Sensulin

Sensulin is a private, preclinical-stage biotech based in San Diego, pioneering a next-generation, glucose-responsive insulin. Founded in 2013, the company leverages a proprietary drug delivery platform to create an insulin that activates in response to high blood sugar and deactivates when glucose normalizes, targeting a fundamental limitation of current insulin therapy. With a seasoned leadership team experienced in diabetes drug development and company building, Sensulin is positioned to address a massive market opportunity if its technology successfully translates through clinical development. The company faces significant technical and competitive risks inherent to its ambitious, platform-defining program.

Proprietary glucose-responsive insulin platform designed to release active insulin in response to high blood glucose and reduce activity when glucose normalizes, aiming to mimic pancreatic function.

Sensulin competes with major diabetes players (Novo Nordisk, Sanofi, Eli Lilly) investing in improved insulin analogs and delivery devices. Its primary technological competitors are advanced automated insulin delivery (AID) systems, which offer a device-based solution to the same problem of hypoglycemia prevention.